ABSTRACT: Welcome editorial from Editor in Chief

ABSTRACT: Background: Personalised medicine through pharmacogenomics is revolutionalizing healthcare delivery by encouraging individualized therapy that takes into consideration an individual's genetic profile, environment and lifestyle. Pharmacogenomics is an aspect of pharmacy that studies the relationship between genetic profile and response to therapeutic agents.  However, the application of the concepts of pharmacogenomics in healthcare helps in achieving more effective and safe responses from therapy. This study evaluates the application and benefits of pharmacogenomics in clinical practice based on evidence from current practices in various medical fields.
Methods: In carrying out this review, PubMed database was the primary literature source and we analyzed and synthesized findings from the included literature thematically as it relates to pharmacogenomics applications, benefits and challenges as well as safety and ethical concerns.
Results: Pharmacogenomics has been widely applied in various aspects of healthcare such as in dosing, choice of treatment, reducing and management of adverse reactions, individualization of therapy, optimizing efficacy of therapy. Despite its numerous applications, its adoption faces challenges such as limited clinical evidence, lack of specialized training among healthcare professionals, cost and complexity of genetic mapping as well as ethical concerns. 
Conclusion: With ongoing advances in genomic technologies, pharmacogenomics is becoming an integral aspect of individualization therapy in clinical practice and more widely applied in different healthcare sectors.

ABSTRACT: Hospital-acquired infections (HAIs) continue to be one of the biggest problems for modern healthcare systems, and the problem is getting worse because antimicrobial resistance (AMR) is on the rise. Antibiotics that used to work are quickly losing their effectiveness, which is giving rise to highly adaptable bacteria in clinical settings and turning routine procedures into high-risk situations. This publication examines the intersection of healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) within the framework of smart surveillance—digital, data-driven systems engineered to identify, predict, and disrupt the spread of infections in real time. We examine the historical development of infection surveillance, analyze the epidemiological burden and resistance mechanisms contributing to a covert pandemic, and assess emerging technologies such as electronic health record integration, machine-learning analytics, genomic sequencing, and Internet of Things (IoT) sensor networks. These new ideas give us new ways to prevent infections before they happen, but they also bring up difficult moral, legal, and social problems about privacy, fairness, and governance. We contend that intelligent surveillance should be integrated into comprehensive infection prevention frameworks and antimicrobial stewardship initiatives to establish resilient hospitals. By combining predictive analytics with basic IPC procedures, ethical monitoring, and giving workers more autonomy, healthcare organizations may turn passive surveillance into active defense. In the end, winning the war against HAIs will depend not just on cutting-edge technology, but also on how it is used with care, honesty, and openness.